|
|
| CAS-Nr. | 134523-03-8 |
| Bezeichnung: | |
| Englisch Name: | Atorvastatin calcium |
| Synonyma: |
Tahor;ci-981;YM-548;Sortis;LIPITOR;pd134298-38a;ATORVASTATIN CA;Atorvastatin 3S,5S-Atorvastatin;Alorvastin calcium |
| CBNumber: | CB4260130 |
| Summenformel: | C66H68CaF2N4O10 |
| Molgewicht: | 1155.36 |
| MOL-Datei: | 134523-03-8.mol |
|
|
|
|
| Atorvastatin calcium physikalisch-chemischer Eigenschaften |
|
|
| storage temp. : |
Store at +4°C |
|
|
|
|
Atorvastatin calcium Chemische Eigenschaften,Einsatz,Produktion Methoden |
Chemische Eigenschaften
White Crystalline Powder |
|
Verwenden
A selective, competitive HMG-CoA reductase inhibitor. The only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia |
|
Verwenden
A selective, competitive HMG-CoA reductase inhibitor. Atorvastatin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia. |
|
Verwenden
antihyperlipidemic, HMGCoA reductase inhibitor |
|
Verwenden
DMSO and EtOH soluble |
|
Verwenden
The primary uses of atorvastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease. |
|
R-Sätze Betriebsanweisung:
R20/21/22:Gesundheitsschädlich beim Einatmen,Verschlucken und Berührung mit der Haut.
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut. |
|
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen. |
|
Biologische Aktivit?t
Potent HMG-CoA reductase inhibitor (IC 50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model. |
|
|
| Atorvastatin calcium Upstream-Materialien And Downstream Produkte |
Upstream-Materialien
|
Downstream Produkte
|
| Atorvastatin calcium Anbieter Lieferant Produzent Hersteller Vertrieb Händler. Global( 246)Lieferanten |
|
|
|
|
|
|
134523-03-8
LIPITOR
ATORVASTATIN CALCIUM SALT
ATORVASTATIN CALCIUM
ATORVASTATIN CA
[r-(r*, r*)]-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocarbonyl)-1h-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt
1h-pyrrole-1-heptanoicacid,beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methy
calciumsalt(2:1),(r-(r*,r*))-lethyl)-3-phenyl-4-((phenylamino)carbonyl)
ci-981
delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-betcalci1h-pyrrole-1-heptanoicaci
pd134298-38a
ATORVASTATINCALCUIM
Atrovastatin calcium
(3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcarbamoyl) Pyrrol-1-yl]-3 ,5 -Dihydroheptanoic Acid, calcium salt (2:1) Trihydrate
3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcarbamoyl) Pyrrol-1-yl]-3 ,5 ydroheptanoic Acid, calcium salt (2:1) Trihydrate
Atorvastatin Calclum
ATORVASTATIN CALCIUM MM(CRM STANDARD)
ATORVASTATINE CADIUM
Atorvastatinecalcium
C66H68CaF2N4O10
(bR,dR)-2-(4-Fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid
3S,5S-Atorvastatin
Alorvastin calcium
delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-bet calci1h-pyrrole-1-heptanoic acid
C66H68CaFN4O10
Active Pharmaceutical Ingredients
[R-(R*, R*)]-7-[2-(4-Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocarbonyl)-1H-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt
C33H34FN2O52CaC66H68CaF2N4O10
(3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)-1H-PYRROL-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID CALCIUM
(3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-
(R,dR)-2-(4-Fluorophenyl)-,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium
3S,5S-Atorvastatin Calcium
Inhibitors
Intermediates & Fine Chemicals
Pharmaceuticals
C33H35FN2O5Ca
Atorvastatin
C33H35FN2O512Ca
Bis[(3R,5R)-3,5-dihydroxy-7-[2-(1-methylethyl)-3-[(phenylamino)carbonyl]-4-phenyl-5-(4-fluorophenyl)-1H-pyrrol-1-yl]heptanoic acid]calcium salt
Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-yl]-3,5-dihydroxyheptanoic acid] calcium salt
Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-1-pyrrolyl]-3,5-dihydroxyheptanoic acid] calcium salt
YM-548
C66H70Ca3F2N4O11
2C33H34FN2O5Ca
AtorvastatinCaliciumsalt
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (.beta.R,.delta.R)-
(R,R)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacidhemicalciumsalt
Atorvastatin hemicalcium salt
C33H34FN2O5189Ca
(3R,5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl- 4-(Pheynylcarbamoyl)Pyrrol-1-yl]-3,5–Dihydroheptanoic Acid, calcium salt
Atorvastatin calciuM salt trihydrate
beta,delta-dihydroxy--2-(4-fluorophenyl)-5-(1-Methylethyl)-3-phenyl-4-((phenylaMino)carbonyl)-calciun salt(2:1)
Pyrrole-1-heptanoic acid
Atorvastatin CalciuM Trihydrate
Aromatics
Chiral Reagents
Pfizer compounds
Pharmaceutical intermediates
|